Buda Juice, Inc.BUDA

Buda Juice, Inc. likes to describe itself as a wellness innovator, but its latest filing reads more like a cautionary tale about customer concentration dressed up as growth. Revenue for the quarter to 31 March 2026 was $3.5 million, up 17.7% year on year, and the company trumpets a 37% rise in free cash flow. The fine print, however, reveals that a single customer accounted for 96% of sales in both years-meaning Buda’s “platform” is effectively a very tall straw into one big glass. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/2079720/000149315226023043/form10-q.htm; Press Release dated 2026-05-13, https://www.sec.gov/Archives/edgar/data/2079720/000149315226023372/ex99-1.htm)

The balance sheet is structurally sound but small. Net income was $388,000 on 12,351 diluted shares, good for $0.03 of EPS. Assets stand at $22.9 million, mostly equity on the liability side ($21 million), with just $1.8 million of liabilities-so the company isn’t haemorrhaging cash or drowning in debt. Net cash from operations was a healthy $1.3 million, and capex for the quarter was a modest $218,000, while inventory rose $97,000. In other words, Buda is generating cash and keeping the lights on, but it is still a single-digit-million-revenue micro-cap with a single-customer dependency. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/2079720/000149315226023043/form10-q.htm)

Public filings show the firm has been busy tidying its disclosure wardrobe: on 15 May 2026 it filed an 8-K to disclose a routine investor presentation, and on 21 May it lodged a certificate confirming the accuracy of its prior 10-Q. The company also submitted an S-8 shelf registration on 21 April 2026, a standard move when boards want to keep the share register “flexible.” A 13G filed on 2 April 2026 disclosed a passive holder with a 5% stake-hardly a deep-pocketed strategic partner. (source: BUDA 8-K (2026-05-15), https://www.sec.gov/Archives/edgar/data/2079720/000149315226023372/form8-k.htm; BUDA CERT (2026-05-21), https://www.sec.gov/Archives/edgar/data/2079720/000087688226000009/BUDA052126.pdf; BUDA S-8 (2026-04-21), https://www.sec.gov/Archives/edgar/data/2079720/000149315226018153/forms-8.htm; BUDA SCHEDULE 13G (2026-04-02), https://www.sec.gov/Archives/edgar/data/2079720/000149315226014921/xslSCHEDULE_13G_X02/primary_doc.xml)

The company’s investor deck highlights “first full quarter as a public company,” but the filings do not contain formal FY26 guidance. Instead, management flags a “mid-teens outlook” in the May press release, a phrasing that gives wiggle room for anything between 10% and 20%. With 96% of revenue tied to one buyer, the margin of error is the width of one smoothie cup. For context, the free-float is thin enough that the stock has spent most of its listed life in the sub-penny range, and daily volume is a trickle rather than a torrent. (source: Press Release dated 2026-05-13, https://www.sec.gov/Archives/edgar/data/2079720/000149315226023372/ex99-1.htm; SEC submissions JSON, https://data.sec.gov/submissions/CIK0002079720.json)

If you want a chart, the XBRL machine-readable facts live here, but the filings themselves do not supply any valuation commentary, technical levels, or market-cap ranks-because Buda is still a micro-cap wrapped in a wellness story rather than a momentum ticker. The source rail stops at the balance sheet, not the tape. (source: SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0002079720.json; SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=2079720)